• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Acuson breaks $100 million barrier

Article

Acuson is realizing the benefits from its release last year of the Aspen and Sequoia ultrasound scanners. The Mountain View, CA-based vendor reported record revenues for the first quarter of 1997 (end-March) of $107.6 million, a 27% jump over the $84.8

Acuson is realizing the benefits from its release last year of the Aspen and Sequoia ultrasound scanners. The Mountain View, CA-based vendor reported record revenues for the first quarter of 1997 (end-March) of $107.6 million, a 27% jump over the $84.8 million reported in first quarter 1996. Net income totaled $5.8 million, compared with $1.3 million for the same period in 1996. Earnings per share were above analysts' expectations for the quarter.

It was the first quarter for Acuson that exceeded $100 million in revenues and represented the third straight record quarter for sales. Acuson executives credited the success of the Sequoia and Aspen platforms and a strong worldwide ultrasound market as key factors behind the prosperous financial results.

Acuson's revenues surpassed those of arch rival ATL, which reported first-quarter sales of $100.1 million. ATL has usually reported higher revenues than Acuson since the Bothell, WA, company's acquisition of Interspec in 1994.

Acuson also benefited from two large orders in the first quarter. Diagnostic Health Services purchased 22 scanners, primarily Aspen systems, and Henry Ford Hospital in Detroit acquired nine Sequoia C256 echocardiography units (SCAN 4/30/97). Some revenue from those sales will also be realized in the second quarter, according to Stephen Johnson, CFO.

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.